France · Delayed Price · Currency is EUR Neovacs Statistics
Total Valuation
Neovacs has a market cap or net worth of EUR 12,709. The enterprise value is 144,859.
| Market Cap | 12,709 |
| Enterprise Value | 144,859 |
Important Dates
The next estimated earnings date is Friday, December 4, 2026.
| Earnings Date | Dec 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neovacs has 159,064 shares outstanding.
| Current Share Class | 159,064 |
| Shares Outstanding | 159,064 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.02 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.60, with a Debt / Equity ratio of 0.04.
| Current Ratio | 0.60 |
| Quick Ratio | 0.56 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.13 |
Financial Efficiency
Return on equity (ROE) is -22.29% and return on invested capital (ROIC) is -15.99%.
| Return on Equity (ROE) | -22.29% |
| Return on Assets (ROA) | -13.27% |
| Return on Invested Capital (ROIC) | -15.99% |
| Return on Capital Employed (ROCE) | -26.31% |
| Weighted Average Cost of Capital (WACC) | -36.61% |
| Revenue Per Employee | 50,637 |
| Profits Per Employee | -255,683 |
| Employee Count | 20 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -426,032 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.98% in the last 52 weeks. The beta is -1,328.96, so Neovacs's price volatility has been lower than the market average.
| Beta (5Y) | -1,328.96 |
| 52-Week Price Change | -99.98% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 4.72 |
| Relative Strength Index (RSI) | 23.09 |
| Average Volume (20 Days) | 204,851 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neovacs had revenue of EUR 810,199 and -4.09 million in losses.
| Revenue | 810,199 |
| Gross Profit | -1.85M |
| Operating Income | -4.81M |
| Pretax Income | -4.52M |
| Net Income | -4.09M |
| EBITDA | -3.39M |
| EBIT | -4.81M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 9,138 in cash and 704,609 in debt, with a net cash position of -695,471 or -4.37 per share.
| Cash & Cash Equivalents | 9,138 |
| Total Debt | 704,609 |
| Net Cash | -695,471 |
| Net Cash Per Share | -4.37 |
| Equity (Book Value) | 17.81M |
| Book Value Per Share | n/a |
| Working Capital | -1.58M |
Cash Flow
In the last 12 months, operating cash flow was -4.16 million and capital expenditures -3,183, giving a free cash flow of -4.17 million.
| Operating Cash Flow | -4.16M |
| Capital Expenditures | -3,183 |
| Depreciation & Amortization | 1.41M |
| Net Borrowing | 1.63M |
| Free Cash Flow | -4.17M |
| FCF Per Share | -26.20 |
Margins
| Gross Margin | -228.69% |
| Operating Margin | -593.40% |
| Pretax Margin | -557.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neovacs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -29,767.31% |
| FCF Yield | -30,327.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on June 23, 2026. It was a reverse split with a ratio of 0.0001.
| Last Split Date | Jun 23, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.0001 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |